Showing results (301-310 of 437) with videos related to

Sort By:
Pageof 44
Bioorganic & Medicinal Chemistry|December 21, 2022
Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonistsDouglas L Orsi, Steven J Ferrara, Stephan Siegel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2008
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancerJussi P Koivunen, Craig Mermel, Kreshnik Zejnullahu, et al.
Cancer Cell|March 12, 2015
A functional landscape of resistance to ALK inhibition in lung cancerFrederick H Wilson, Cory M Johannessen, Federica Piccioni, et al.
Journal of Medicinal Chemistry|October 25, 2024
Discovery and Characterization of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran In Vivo-Active KAT6AB InhibitorAntonius Ter Laak, Roman C Hillig, Steven J Ferrara, et al.
Genes, Chromosomes & Cancer|December 8, 2007
SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patientsKenneth D Swanson, Jordan M Winter, Marcelo Reis, et al.
Plos One|September 26, 2013
Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequencyMegan C Hanna, Christina Go, Christine Roden, et al.
Cancer Research|July 18, 2008
Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistanceTakeshi Shimamura, Danan Li, Hongbin Ji, et al.
Cancer Research|December 18, 2004
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemiaMohamed Bentires-Alj, J Guillermo Paez, Frank S David, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2009
Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomasDariush Etemadmoghadam, Anna deFazio, Rameen Beroukhim, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 6, 2009
HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapySamanthi A Perera, Danan Li, Takeshi Shimamura, et al.
Pageof 44